Form 4: Y-mAbs Therapeutics Director James Healy Reports Stock and Option Transactions

Director James Healy reported the acquisition of restricted stock units and stock options, as well as the disposal of common stock.

Summary

• On June 11, 2024, James Healy, a director of Y-mAbs Therapeutics, reported transactions involving the company's securities.
• Healy acquired 3,495 restricted stock units (RSUs) and 14,545 stock options.
• He also disposed of 3,495 shares of common stock.
• Following these transactions, Healy directly owns 31,603 shares of common stock and indirectly owns 2,194,278 shares.
• The RSUs vest on the earlier of the first anniversary of the grant date or the date immediately preceding the 2025 annual meeting, contingent upon continued service.
• The stock options vest in equal monthly installments until the first anniversary of the grant date and are exercisable immediately upon vesting.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing showing stock and option transactions. The acquisition of options is a positive, but the disposal of a small amount of stock is slightly negative.

Positives

• The granting of RSUs and stock options to a director can be seen as an incentive to align their interests with the company's success.

Negatives

• The disposal of common stock by a director could be perceived negatively by investors, although the quantity is small.

Risks

• The vesting of RSUs and stock options is contingent upon the Reporting Person's continued service to the Issuer, which introduces a retention risk.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Stakeholder Impact

• The transactions reported in this filing provide stakeholders with insights into the actions of a key company director.

Key Dates